Quick Answer
AN2 Therapeutics, Inc. reported Operating Income Loss of -$38.11 million for the year ending 2025.
- AN2 Therapeutics, Inc. showed an increase of +32.9% in Operating Income Loss from 2024 to 2025.
- This data is from AN2 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), AN2 Therapeutics, Inc.'s Operating Income Loss has declined by 76.6%.
- Historical annual values: Fiscal year 2025: -$38.11 million | Fiscal year 2024: -$56.79 million | Fiscal year 2023: -$69.64 million | Fiscal year 2022: -$42.26 million | Fiscal year 2021: -$21.57 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: